These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23307252)

  • 1. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Lairson DR; Parikh RC; Cormier JN; Du XL
    Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
    Kupryjanczyk J; Kraszewska E; Ziolkowska-Seta I; Madry R; Timorek A; Markowska J; Stelmachow J; Bidzinski M;
    BMC Cancer; 2008 Jan; 8():27. PubMed ID: 18230133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
    Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ
    Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
    Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
    Eisenhauer EL; Tew WP; Levine DA; Lichtman SM; Brown CL; Aghajanian C; Huh J; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Aug; 106(2):381-7. PubMed ID: 17509673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
    Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
    PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
    Kavanagh J; Tresukosol D; Edwards C; Freedman R; Gonzalez de Leon C; Fishman A; Mante R; Hord M; Kudelka A
    J Clin Oncol; 1995 Jul; 13(7):1584-8. PubMed ID: 7602347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
    Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer.
    Nurgalieva Z; Xia R; Liu CC; Burau K; Hardy D; Du XL
    Am J Ther; 2010; 17(2):148-58. PubMed ID: 19417586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MMK; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Dec; 147(3):565-571. PubMed ID: 29056442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer.
    Nurgalieva Z; Liu CC; Du XL
    Int J Gynecol Cancer; 2009 Nov; 19(8):1314-21. PubMed ID: 20009883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.